New York, USA – 19th September 2025
GPN Vaccines Inc (USA) today announces the retirement of Prof. James Paton as a Director and the appointment of Dr. Bruce Forrest as an Executive Director to the Board of GPN Vaccines Inc. Dr. Forrest is the Company’s Chief Scientific Officer (CSO), and he brings a wealth of scientific and clinical experience on development of innovative vaccines that have received FDA approval and been launched worldwide.
The company acknowledges the seminal contribution of Prof. James Paton as both a founding director of GPN Vaccines and the Company’s inaugural CSO. James will assume the role as senior advisor to GPN Vaccines Pty Ltd, the Australian based and wholly owned operational subsidiary of GPN Vaccines Inc and will continue to provide valuable contributions as a leading expert on the pathogenesis of Streptococcus pneumoniae.
Prof. Tim Hirst, Chairman and CEO of GPN Vaccines Inc commented “ I would like to sincerely thank James for his dedication and guidance as a founding director of GPN Vaccines. His deep understanding of the pneumococcus has been central to the development of Gamma-PN as a revolutionary vaccine for the prevention of pneumococcal disease. I also welcome Bruce Forrest to his elevation to the Board of GPN Vaccine Inc.”
Dr. Bruce Forrest commented. “It has been a privilege to contribute to GPN Vaccines’ strategy and development programs, and I am delighted to now join the Board to help advance our mission. This is an exciting time for the company, and I look forward to working with the team to progress the clinical development of Gamma-PN and our broader vaccine pipeline”.
GPN Vaccines (AUS), is a wholly owned subsidiary of GPN Vaccines Inc and today the Australian Securities and Investments Commission (ASIC) formally approved its conversion from a public (unlisted) company limited by shares (Ltd) to a proprietary limited company, GPN Vaccines Pty Ltd. Concomitant with these changes, Manon Cox, Ismail Kola and Barry Palte (who remain as directors of GPN Vaccines Inc), and James Paton, have resigned as directors of GPN Vaccines Pty Ltd, with James Selkirk, the Company’s Chief Financial Officer being appointed a Director of GPN Vaccines Pty Ltd. The current directors and officers of GPN Vaccines Pty Ltd are Tim Hirst and James Selkirk; with Eve Martin as Company Secretary.
About GPN Vaccines Inc
GPN Vaccines Inc is a clinical stage Delaware C-corporation developing vaccines against innovative bacterial vaccines, with its lead vaccine targeting Streptococcus pneumoniae. S. pneumoniae is responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections) and each year causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now more than 100 different serotypes of S. pneumoniae and the best vaccine currently on the market only protects against 21 of them. GPN Vaccines’ product, called Gamma-PN, is being developed to protect children and adults against all S. pneumoniae strains, regardless of serotype.
Media Contact:
Tim Hirst
Chief Executive Officer
tim@gpnvaccines.com
+61 420 942 824
